Acquisition of Artisan Pharma, Inc.

Asahi Kasei Corporation

Our attorneys represented Asahi Kasei Pharma Corporation of Japan in its acquisition of US-based Artisan Pharma, Inc., a drug maker focused on treating blood clotting disorders. The renamed company, Asahi Kasei Pharma America Corporation (AKP Corp.), will serve as a base for the development and commercialization of ART-123, a human thrombomodulin being developed for the treatment of disseminated intravascular coagulation in sepsis and deep vein thrombosis. Asahi Kasei Pharma established Artisan Pharma in 2006 together with several other venture capital firms for the advancement of overseas development of ART-123 but subsequently concluded that it would be optimal to acquire full ownership.


Email Disclaimer